Drug Trial Radar · NCT01423747
Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia
Last checked: Nov 20, 2026Latest source record: Jun 26, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
400
Planned (sponsor's estimate)
Start
Jul 2003
Primary completion
Sep 2011
Study completion Sep 2016
Sponsor
- Lead sponsor
- St. Anna KinderkrebsforschungAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- International BFM Study Group
- First posted
- Aug 26, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 3 months, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
With this protocol the ALL-SZT BFM international study group wants to evaluate whether hematopoietic stem cell transplantation (HSCT) from matched family or unrelated matched donors (MD) is equivalent to the HSCT from matched sibling donors (MSD). to evaluate the efficacy of haematopoietic stem cell transplantation (HSCT) from mismatched family or unrelated mismatched donors (MMD) as compared to HSCT from matched sibling donor (MSD) and matched donor (MD). to determine whether therapy has been carried out according to the main haematopoietic stem cell transplantation (HSCT) protocol recommendations. The standardisation of the treatment options during haematopoietic stem cell transplantation (HSCT) from different donor types aims at the achievement of an optimal comparison of survival after HSCT with survival after chemotherapy only. to prospectively evaluate and compare the incidence of acute and chronic graft- versus-host-disease (GvHD) after haematopoietic stem cell transplantation (HSCT) from matched sibling donor (MSD), from matched donor (MD) and from mismatched donor (MMD).
Conditions
- Lymphoblastic Leukemia, Acute, Childhood;
Interventions
VP16Drug
patients with MSD receive as conditioning VP16 60mg/kg/d on day -3
TBIRadiation
patients with a MSD receive TBI (12Gy in 6 fractions) as conditioning
VP16, ATGDrug
patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1
TBIRadiation
patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive TBI (12Gy in 6 fractions)
Fludarabine, OKT3, Treosulfan, ThiotepaDrug
patients with a MMD (haploidentical or cord blood) receive Fludarabine 30mg/m²/d on day -9 to -5, ATG 20mg/kd/d on day -3 to day -1, Treosulfan 14g/m²/d on day -7 to -5 and Thiotepa 2x5mg/kg/d on day -4
VP16, ATGDrug
patients with MMD-transplantation (8/10)receive VP16 60mg/kg/d on day -4, ATG from day -3 to day-1 20mg/kg/d
TBIRadiation
patients with a MMD-transplantation (8/10) receive 12 Gy in 6 fractions
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-free and overall survival after allogeneic haematopoietic stem cell transplantation (HSCT)Time frame: 14 years
Locations
24 sites in 2 countries. Site status is shown where the registry gives one.
Universitätsklinik für Kinder- und Jugendheilkunde, Klin. Abt. f. Hämato-Onkologie
Graz, Austria
Universitätsklinik für Kinder- und Jugendheilkunde
Innsbruck, Austria
St. Anna Kinderspital
Vienna, Austria
Charité Campus Virchow- Klinikum, Klinikum der Pädiatrie, Onkologie/Hämatologie/KMT
Berlin, Germany
Klinik und Poliklinik für Kinderheilkunde, Hämatologie, Onkologie
Dresden, Germany
Universitätsklinikum Düsseldorf, Klinik f. Kinderonkologie, Hämatologie u. Immunologie
Düsseldorf, Germany
Klinik für Kinder und Jugendliche der Universität Erlangen-Nürnberg
Erlangen, Germany
Universitätsklinikum Essen, Zentrum für Kinderheilkunde, Abt. für Hämatologie/Onkologie
Essen, Germany
Klinik für Kinderheilkunde III, Hämatologie und Onkologie, Johann Wolfgang Goethe Universität
Frankfurt am Main, Germany
Universitätsklinikum Freiburg, Zentrum für Kinderheilkunde und Jugendmedizin, Klinik IV: Päd. Hämatologie und Onkologie
Freiburg im Breisgau, Germany
Zentrum für Kinderheilkunde, Abt. Hämatologie und Onkologie
Giessen, Germany
Klinkum der Med. Fakultät der Martin-Luther-Universität Halle-Wittenberg, Uni. Klinik un Poliklinik für Kinder- und Jugendmedizin
Halle, Germany
Universitätsklinikum Hamburg-Eppendorf, Kinderklinik, Abt. für Hämatologie und Onkologie
Hamburg, Germany
Med. Hochschule Hannover, Päd. Hämatologie und Onkologie
Hanover, Germany
Universitätskinderklinik, Päd. Hämatologie, Onkologie und Immunologie
Heidelberg, Germany
Klinik für Knochenmarktransplantation
Idar-Oberstein, Germany
Klinik für Kinder- und Jugendmedizin
Jena, Germany
Universitätsklinikum Kiel, Klinik für Allgemeine Pädiatrie
Kiel, Germany
Klinikum der Universität München, Dr. von Haunersches Kinderspital, Abt. für Hämatologie / Onkologie
München, Germany
Städt. Krankenhaus München-Schwabing, Universitätskinderklinik der TU
München, Germany
Universitätsklinikum Münster, Klinik und Poliklinik für Kinderheilkunde, päd. Hämatologie / Onkologie
Münster, Germany
Univ.-Klinik für Kinderheilkunde und Jugendmedizin
Tübingen, Germany
Universitätskinderklinik
Ulm, Germany
Universitätsklinik, päd. Onkologie/Stammzelltransplantation
Würzburg, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.